Edgewise Therapeutics, Inc. (EWTX) earnings date
Feb 25, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | before open | 38 | 8-K |
| Q4 FY2024 | Mon, Mar 3, 2025 | before open | 62 | 8-K |
What they guided beta
| Q3 FY2026 | "– Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to initiate by year-end 2026 –" exhibit |
| Q3 FY2026 | "“In HCM, positive CIRRUS-HCM Part D results and our JCI Insight publication reinforce the differentiated profile of EDG-7500, and we expect to initiate our Phase 3 trial by year-end 2026." exhibit |
| Q3 FY2026 | "CIRRUS-HCM was designed to inform a Phase 3 trial, which the Company expects to initiate by the end of 2026." exhibit |
| Q3 FY2026 | "The decrease was primarily attributable to lower costs associated with sevasemten following its sale to Servier in July 2026, partially offset by higher program spend on EDG-7500, discovery and preclinical programs, and personnel-related costs." exhibit |
| Q2 FY2026 | "The company expects to initiate a Phase 3 trial in the fourth quarter of 2026." exhibit |
| Q2 FY2026 | "The company expects to initiate a Phase 2 trial in participants with heart failure with preserved ejection fraction (HFpEF) in the second half of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/EWTX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/EWTX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/EWTX/"><img src="https://veritasdata.dev/embed/EWTX.svg" alt="EWTX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/EWTX/)
Script
<script async src="https://veritasdata.dev/embed/EWTX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/EWTX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.